Johnson & Johnson completes USD 1 billion acquisition of Firefly Bio
JNJ•Johnson & Johnson completes Firefly Bio acquisition
- Johnson & Johnson completed its acquisition of Firefly Bio for USD 1 billion in cash on July 29, 2026.
- The deal adds Firefly’s Firelink degrader antibody conjugate platform to expand oncology capabilities, with a focus on hard-to-treat solid tumors.
- The platform is designed to deliver selective protein degraders to cancer cells, aiming to limit damage to healthy tissue versus existing approaches.
- The transaction strengthens efforts to target pan-KRAS and other cancer drivers through next-generation antibody engineering.
